Device Trial Radar · NCT07039461
Evaluation of Effectiveness and Safety of Intense Pulsed Light Treatment for Chalazion
Last checked: Nov 20, 2026Latest source record: Jan 6, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
4
Actual
Start
Sep 12, 2025
Primary completion
Dec 24, 2025
Study completion Dec 24, 2025
Sponsor
- Lead sponsor
- Lumenis Be Ltd.Not on our public-company list
- Sponsor type
- Industry
- First posted
- Jun 26, 2025
Design
- Study type
- Interventional
- Phase
- Not applicable (typical for device studies)
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, care provider, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated device
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
To study the effectiveness and safety of IPL treatment for Chalazion
Conditions
- Chalazion
Interventions
OptiLIGHTDevice
three IPL or sham treatment in 1 week interval followed by 1 follow-up 4 weeks after the last treatment
Primary outcomes
What the sponsor says the trial is designed to measure.
- The percentage of resolved chalazion 4 weeks after the last treatment in the study group and the control groupTime frame: 4 weeks after the last treatment
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
Manhattan Face and Eye clinic
New York, New York
Periman Eye Institute
Seattle, Washington
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.